| STE |
Report |
Adjusted EPS (Q1 FY27) |
BEAT |
pred ~$2.56 vs. cons $2.52 |
MEDIUM |
| STE |
Report |
Revenue (Q1 FY27) |
IN-LINE |
pred ~$1.50B vs. cons $1.51B |
MEDIUM |
| STE |
Report |
AST constant-currency organic growth (Q1 FY27) |
MISS |
pred ~+4% vs. cons ~+6.5% |
MEDIUM |
| STE |
Guide |
FY27 Adjusted EPS guidance |
UNCHANGED |
guide ~$11.10-$11.30 (mid ~$11.20) vs. cons ~$11.20 (FY2027) |
HIGH |
| STE |
Guide |
FY27 constant-currency organic revenue growth guidance |
UNCHANGED |
guide ~+6-7% (mid ~6.5%) vs. cons ~+6.5% (FY2027) |
MEDIUM |
| STE |
Guide |
FY27 as-reported revenue growth guidance |
UNCHANGED |
guide ~+7-8% (mid ~7.5%) vs. cons ~+7.5% (FY2027) |
MEDIUM |
| STE |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.0% |
— |
MEDIUM |
| STE |
Return |
5-day cumulative residual |
-3.5% (FADE) |
STE enters the print up ~10% idiosyncratically in late July (SPY flat), re-rating expectations into a quarter management itself framed as a soft, back-half-weighted start. Likely outcome is a modest EPS beat but decelerating headline/AST organic growth against tough comps (AST +13%/Healthcare service +13% last Q1), higher ~25% tax rate compressing conversion, and lighter FCF. A 'beat-and-reaffirm' (not raise) early in the fiscal year gives the tape little new to chase; out-period math (soft H1, dependence on unproven H2 AST reacceleration and med-tech destocking bottoming) invites near-term estimate trimming even after a beat, so the run-up fades toward pre-rally levels absent a confident H2 message. |
LOW |